Terms: = Pancreatic cancer AND KRAS, C-K-RAS, 3845, P01116, NS3, KI-RAS, KRAS2, K-RAS4A, K-RAS2A, K-RAS4B, KRAS1, K-RAS2B, RASK2
3344 results:
1. The pRb/RBL2-E2F1/4-GCN5 axis regulates cancer stem cell formation and G0 phase entry/exit by paracrine mechanisms.
Chang CH; Liu F; Militi S; Hester S; Nibhani R; Deng S; Dunford J; Rendek A; Soonawalla Z; Fischer R; Oppermann U; Pauklin S
Nat Commun; 2024 Apr; 15(1):3580. PubMed ID: 38678032
[TBL] [Abstract] [Full Text] [Related]
2. CX-4945 (Silmitasertib) Induces Cell Death by Impairing Lysosomal Utilization in
Lee DS; Han MW; Kang Y; Kim C; Lee S; Kim KP; Yoo C
Anticancer Res; 2024 May; 44(5):1939-1946. PubMed ID: 38677763
[TBL] [Abstract] [Full Text] [Related]
3. Drugging the undruggable: Advances in targeting kras signaling in solid tumors.
Tripathi P; Kumari R; Pathak R
Int Rev Cell Mol Biol; 2024; 385():1-39. PubMed ID: 38663957
[TBL] [Abstract] [Full Text] [Related]
4. A pancreatic cancer organoid-in-matrix platform shows distinct sensitivities to T cell killing.
Lahusen A; Cai J; Schirmbeck R; Wellstein A; Kleger A; Seufferlein T; Eiseler T; Lin YN
Sci Rep; 2024 Apr; 14(1):9377. PubMed ID: 38654067
[TBL] [Abstract] [Full Text] [Related]
5. Targeting kras in cancer.
Singhal A; Li BT; O'Reilly EM
Nat Med; 2024 Apr; 30(4):969-983. PubMed ID: 38637634
[TBL] [Abstract] [Full Text] [Related]
6. Disruption of the pro-oncogenic c-RAF-PDE8A complex represents a differentiated approach to treating kras-c-RAF dependent PDAC.
Cooke SF; Wright TA; Sin YY; Ling J; Kyurkchieva E; Phanthaphol N; Mcskimming T; Herbert K; Rebus S; Biankin AV; Chang DK; Baillie GS; Blair CM
Sci Rep; 2024 Apr; 14(1):8998. PubMed ID: 38637546
[TBL] [Abstract] [Full Text] [Related]
7. Decoding the Versatile Landscape of Autophagic Protein VMP1 in cancer: A Comprehensive Review across Tissue Types and Regulatory Mechanisms.
Renna FJ; Gonzalez CD; Vaccaro MI
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612567
[TBL] [Abstract] [Full Text] [Related]
8. A glycolytic metabolite bypasses "two-hit" tumor suppression by BRCA2.
Kong LR; Gupta K; Wu AJ; Perera D; Ivanyi-Nagy R; Ahmed SM; Tan TZ; Tan SL; Fuddin A; Sundaramoorthy E; Goh GS; Wong RTX; Costa ASH; Oddy C; Wong H; Patro CPK; Kho YS; Huang XZ; Choo J; Shehata M; Lee SC; Goh BC; Frezza C; Pitt JJ; Venkitaraman AR
Cell; 2024 Apr; 187(9):2269-2287.e16. PubMed ID: 38608703
[TBL] [Abstract] [Full Text] [Related]
9. Genetic Signature of Human pancreatic cancer and Personalized Targeting.
Reshkin SJ; Cardone RA; Koltai T
Cells; 2024 Mar; 13(7):. PubMed ID: 38607041
[TBL] [Abstract] [Full Text] [Related]
10. Nardilysin-regulated scission mechanism activates polo-like kinase 3 to suppress the development of pancreatic cancer.
Fu J; Ling J; Li CF; Tsai CL; Yin W; Hou J; Chen P; Cao Y; Kang Y; Sun Y; Xia X; Jiang Z; Furukawa K; Lu Y; Wu M; Huang Q; Yao J; Hawke DH; Pan BF; Zhao J; Huang J; Wang H; Bahassi EIM; Stambrook PJ; Huang P; Fleming JB; Maitra A; Tainer JA; Hung MC; Lin C; Chiao PJ
Nat Commun; 2024 Apr; 15(1):3149. PubMed ID: 38605037
[TBL] [Abstract] [Full Text] [Related]
11. IFNα-induced BST2
Zheng C; Wang J; Zhou Y; Duan Y; Zheng R; Xie Y; Wei X; Wu J; Shen H; Ye M; Kong B; Liu Y; Xu P; Zhang Q; Liang T
Cell Rep; 2024 Apr; 43(4):114088. PubMed ID: 38602878
[TBL] [Abstract] [Full Text] [Related]
12. Macrophage-induced reactive oxygen species in the initiation of pancreatic cancer: a mini-review.
Döppler HR; Storz P
Front Immunol; 2024; 15():1278807. PubMed ID: 38576613
[TBL] [Abstract] [Full Text] [Related]
13. STAT3 is a genetic modifier of TGF-beta induced EMT in kras mutant pancreatic cancer.
D'Amico S; Kirillov V; Petrenko O; Reich NC
Elife; 2024 Apr; 13():. PubMed ID: 38573819
[TBL] [Abstract] [Full Text] [Related]
14. [The use of targeted therapies in gastrointestinal oncology].
Lange S
Dtsch Med Wochenschr; 2024 Apr; 149(8):440-446. PubMed ID: 38565117
[TBL] [Abstract] [Full Text] [Related]
15. IL-2 promotes expansion and intratumoral accumulation of tumor infiltrating dendritic cells in pancreatic cancer.
Gong T; Huang X; Wang Z; Chu Y; Wang L; Wang Q
Cancer Immunol Immunother; 2024 Mar; 73(5):84. PubMed ID: 38554155
[TBL] [Abstract] [Full Text] [Related]
16. Undifferentiated Carcinoma with Osteoclast-like Giant Cells of the Pancreas: Molecular Genetic Analysis of 13 Cases.
Hrudka J; Kalinová M; Ciprová V; Moravcová J; Dvořák R; Matěj R
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542259
[TBL] [Abstract] [Full Text] [Related]
17. Activation of endogenous retroviruses and induction of viral mimicry by MEK1/2 inhibition in pancreatic cancer.
Cortesi A; Gandolfi F; Arco F; Di Chiaro P; Valli E; Polletti S; Noberini R; Gualdrini F; Attanasio S; Citron F; Ho IL; Shah R; Yen EY; Spinella MC; Ronzoni S; Rodighiero S; Mitro N; Bonaldi T; Ghisletti S; Monticelli S; Viale A; Diaferia GR; Natoli G
Sci Adv; 2024 Mar; 10(13):eadk5386. PubMed ID: 38536927
[TBL] [Abstract] [Full Text] [Related]
18. Combined kras-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer.
Bulle A; Liu P; Seehra K; Bansod S; Chen Y; Zahra K; Somani V; Khawar IA; Chen HP; Dodhiawala PB; Li L; Geng Y; Mo CK; Mahsl J; Ding L; Govindan R; Davies S; Mudd J; Hawkins WG; Fields RC; DeNardo DG; Knoerzer D; Held JM; Grierson PM; Wang-Gillam A; Ruzinova MB; Lim KH
Nat Commun; 2024 Mar; 15(1):2503. PubMed ID: 38509064
[TBL] [Abstract] [Full Text] [Related]
19. pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection.
Brozos-Vázquez E; Toledano-Fonseca M; Costa-Fraga N; García-Ortiz MV; Díaz-Lagares Á; Rodríguez-Ariza A; Aranda E; López-López R
Cancer Treat Rev; 2024 Apr; 125():102719. PubMed ID: 38490088
[TBL] [Abstract] [Full Text] [Related]
20. First-in-Class Humanized Antibody against Alternatively Spliced Tissue Factor Augments Anti-Metastatic Efficacy of Chemotherapy in a Preclinical Model of pancreatic Ductal Adenocarcinoma.
Lewis CS; Backman C; Ahsan S; Cliff A; Hariharan A; Yeh JJ; Zhang X; Xie C; Sohal DPS; Bogdanov VY
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473827
[TBL] [Abstract] [Full Text] [Related]
[Next]
